A boy has died in Pfizer’s phase 2 study of its gene therapy candidate for Duchenne muscular dystrophy, a rare genetic disorder that primarily affects boys, according to a patient advocacy group.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
